Gilberto Lopes
Jun 2, 2025, 17:43
Gilberto Lopes Highlights Key Insights from Lung Oral Session at ASCO25
Gilberto Lopes, Medical Director for International Programs and Associate Director at the Sylvester Comprehensive Cancer Center at University of Miami, shared a post on X:
“And of course: Lung Oral session
My take so far:
Krystal 7 IO + adagrasib is interesting as it was tolerated, but efficacy does not seem to be better than with IO alone or with chemo. Will need to wait for and see randomized trial
Dato shows interesting first line data with IO
Zipalertinib clearly active in EGFR ex20 (even after Ami)
BAY 2927088 shows very promising activity in people with lung cancer and HER2 mutations
Savolitinib + Osi have better PFS than chemo after EGFR TKIs 1st-3rd gen) and with MET amp – new option?
Patri improved PFS marginally and is unlikely to dethrone platinum chemo after 3rd gen TKI alone
Sacituzumab improves RR, PFS, and OS v docetaxel after EGFR TKI and platinum chemo and is likely to become a preferred option”
More posts featuring Gilberto Lopes.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 3, 2025, 16:39